North York Research Inc.

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Psoriasis4 trials
• Vitiligo4 trials
• Atopic dermatitis (eczema)3 trials
• Hidradenitis suppurativa2 trials

Phase

• Phase 39 trials
• Phase 23 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Active, not recruiting8 trials
• Completed4 trials
• Recruiting2 trials

Lead sponsor

• Pfizer5 trials
• Alumis Inc2 trials
• Apollo Therapeutics Ltd1 trial
• Bluefin Biomedicine, Inc.1 trial
• Bristol-Myers Squibb1 trial
• and 4 more

Running trials

• Recruiting

  A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

  NCT07599813· Phase 2· Apollo Therapeutics Ltd· Source

  Contact: North York Research Inc.

• Active, not recruiting

  A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

  NCT07228390· Phase 2· Pfizer· Source

• Active, not recruiting

  A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

  NCT07287644· Phase 2/3· Bluefin Biomedicine, Inc.· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

  NCT07108283· Phase 2· Takeda· Source

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Bristol-Myers Squibb· Source

  Contact: Firouzeh Niakosari, Site 0042

• Active, not recruiting

  Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

  NCT06846541· Phase 3· Alumis Inc· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

  NCT06516965· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

  NCT06220604· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

  NCT06163326· Phase 3· Pfizer· Source

• Active, not recruiting

  A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

  NCT06072183· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)1 recruiting
• Psoriasis1 recruiting

Closed trials

• Completed

  A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

  NCT07006792· Phase 4· Eli Lilly and Company· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06586112· Phase 3· Alumis Inc· Source

• Completed

  A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

  NCT05583526· Phase 3· Pfizer· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source